Investor.precisionbiosciences.com
Precision BioSciences Completes Spin-Out of Elo Life Systems
WebDURHAM, N.C.--(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of …
Actived: 5 days ago
Precision BioSciences Presents Late-Breaking Data Highlighting
Web- PBGENE-HBV designed to both eliminate cccDNA and inactivate HBV DNA - Data demonstrates strong proof of concept efficacy including up to 99% viral engagement and no detectable off-target editing at maximal on-target editing dose - PBGENE-HBV final clinical candidate ready with CTA and/or IND filing targeted in 2024 - …
Precision BioSciences Announces In Vivo Gene Editing
Web- Precision to Receive $75 Million Upfront for a Single Target; Precision Eligible to Receive up to an Additional $1.4 Billion in Milestones and Tiered Royalties on Sales of Licensed Products - Precision to Develop a Single ARCUS ® Nuclease Designed for Safe and Efficient In Vivo Gene Insertion -
New Preclinical Data Presented at the 2021 American Society of …
WebResults Show Promising Gene Editing Approach for Transthyretin Amyloidosis . DURHAM, N.C.--(BUSINESS WIRE)--May 11, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, …
Precision BioSciences and iECURE Announce License and …
WebiECURE to License Precision’s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to iECURE iECURE Expects to File a Clinical Trial Application as Early as 2022 for Precision’s
Precision BioSciences Announces Oral Presentation of Positive …
Web- High antiviral activity with substantial and durable reductions in hepatitis B serum antigen and covalently closed circular DNA in preclinical studies of PBGENE-HBV - Supports continued PBGENE-HBV development and planned submission of CTA/IND application DURHAM, N.C. --(BUSINESS WIRE)--Jun.
Precision BioSciences Announces Preclinical Data Showcasing …
WebMultiple Oral Presentations and Posters to Demonstrate Differentiated Attributes of ARCUS® Genome Editing Platform for Efficient Gene Insertion and Gene Knockout New Primary Hyperoxaluria Type 1 (PH1) Preclinical Data Demonstrate a Robust ARCUS Nuclease Optimization Process Leading to 98% Knockdown
Precision BioSciences Announces Publication in Molecular Therapy …
Web- ARCUS Genome Editing Achieved Substantial Reductions in both cccDNA and Hepatitis B Surface Antigen (HBsAg), 85% and 77% respectively, in HBV-infected Primary Human Hepatocytes (PHH) - Significant Decrease in HBsAg and High On-target Editing Achieved in Novel Mouse and Non-human Primate Models
Precision BioSciences Welcomes Healthcare Industry Expert, Kevin …
WebDURHAM, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today that Kevin J. Buehler, former CEO of Alcon Laboratories, has been appointed to its Board of Directors, …
Precision BioSciences Strengthens Board of Directors with …
WebDURHAM, N.C., March 11, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced today that Geno Germano, President and CEO of Elucida Oncology, has been appointed to the …
Precision BioSciences Outlines Clinical Development Strategy for In
Web- Accelerated Clinical Development Expected to Enable Three Investigational New Drug/Clinical Trial Applications Within Next Three Years, Including for Familial Hypercholesterolemia as early as 2022, Primary Hyperoxaluria Type 1 in 2023, and Chronic Hepatitis B in 2024 - Announced Licensing and
Events & Presentations
WebGlobal Hepatitis Summit 2023 Presentation - A gene editing approach for chronic hepatitis B: Elimination of hepatitis B virus in vivo by targeting cccDNA and integrated viral genomes with a sequence-specific ARCUS nuclease. Apr 26, 2023 at 8:30 AM CEST. View Presentation.
Precision BioSciences Receives U.S. Patent Allowance Covering …
WebDURHAM, N.C.--(BUSINESS WIRE)--Sep. 27, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced it has …
Precision BioSciences Receives Initial $7.5 Million Cash Payment …
WebDURHAM, N.C.--(BUSINESS WIRE)--Feb. 12, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today received an upfront cash …
Mid-Year 2022 Allogeneic CAR T Pipeline Update
WebPBCAR0191 potential first in class allogeneic therapy for CAR T relapsed patients (median 5+ priorlines) with highest unmet need. Efficacy1: 100% Response Rate, 73% Complete Response in first 11 evaluable CAR T relapsed subjects. 50% ≥ 6-month Duration-of-Response in evaluable subjects.
Precision BioSciences Completes Strategic Transaction with …
Web- Precision Eligible to Receive up to $227 Million in Upfront Economics and Milestone Payments for Azer-Cel in Addition to Double-Digit Royalties on Sales - Imugene to Assume Control of Precision’s Cell Therapy Infrastructure in Pursuit of Biologics License Application for Azer-Cel in LBCL Patients
Precision BioSciences Announces Publication in Nature …
Web- Publication validates unique ability of ARCUS genome editing to preferentially target and eliminate mutant m.3243G mitochondrial DNA (mtDNA) with high specificity - mitoARCUS efficiently shifted m.3243A>G heteroplasmy without off-target activity, leading to an overall improvement in mitochondrial
Precision BioSciences Presents Analysis of Azer-Cel
Web- Cryopreserved, Post-thaw CAR T Cell Composition and Effective CAR T Cell Dose are Predictive for Response to Treatment with Azer-cel - Peak CAR T Expansion, a Key Determinant of Durable Response, Strongly Correlated with Effective CAR T Dose DURHAM, N.C.--(BUSINESS WIRE)--Dec. 10, 2022-- Precision BioSciences (Nasdaq: …
Elo Life Systems Appoints Food and Beverage Industry
WebDurham, N.C., September 21, 2020 – Elo Life Systems, a food and agriculture company with a mission to improve human health and wellness, today announced that Alec Hayes, Ph.D., has joined Elo Life Systems as Vice President of Technology and Products. In his role, Alec will be responsible for Elo’s research and development pipeline and strategic expansion …
Top Categories
Popular Searched
› Healthy peanut butter chicken recipe
› Crowne healthcare fort payne al
› Public health primary care burien
› Wales mental health guidelines
› Healthy blue missouri precertification form
› Iu health arnett general surgery map
Recently Searched
› Prime health care pc glastonbury
› Florida health care provider line
› First financial health savings account
› Suncloud health care providers
› Supplements for healthy ovaries
› Denver health pharmacy disposal bins
› Capital health quakerbridge nj
› Mywellbrook behavioral health nj